|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Venugopal R, Bavle RM, Konda P,
Muniswamappa S and Makarla S: Familial cancers of head and neck
region. J Clin Diagn Res. 11:ZE01–ZE06. 2017.PubMed/NCBI
|
|
3
|
Cao SM, Simons MJ and Qian CN: The
prevalence and prevention of nasopharyngeal carcinoma in China.
Chin J Cancer. 30:114–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee AW, Ma BB, Ng WT and Chan AT:
Management of nasopharyngeal carcinoma: Current practice and future
perspective. J Clin Oncol. 33:3356–3364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang MX, Li J, Shen GP, Zou X, Xu JJ,
Jiang R, You R, Hua YJ, Sun Y, Ma J, et al: Intensity-modulated
radiotherapy prolongs the survival of patients with nasopharyngeal
carcinoma compared with conventional two-dimensional radiotherapy:
A 10-year experience with a large cohort and long follow-up. Eur J
Cancer. 51:2587–2595. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruuskanen M, Grenman R, Leivo I, Vahlberg
T, Mäkitie A, Saarilahti K, Wigren T, Korpela M, Voutilainen L,
Koivunen P, et al: Outcome of nasopharyngeal carcinoma in Finland:
A nationwide study. Acta Oncol. 57:251–256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen X, Zhu X, Liang Z, Li L, Qu S, Chen K
and Pan X: Long-term outcomes of neoadjuvant chemotherapy followed
by concurrent chemoradiotherapy (CCRT) vs CCRT alone for
nasopharyngeal carcinoma in the era of intensity-modulated
radiation therapy using propensity score matching method.
OncoTargets Ther. 10:2909–2921. 2017. View Article : Google Scholar
|
|
8
|
Ribassin-Majed L, Marguet S, Lee AWM, Ng
WT, Ma J, Chan ATC, Huang PY, Zhu G, Chua DTT, Chen Y, et al: What
is the best treatment of locally advanced nasopharyngeal carcinoma?
An individual patient data network meta-analysis. J Clin Oncol.
35:498–505. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harte PJ, Wu W, Carrasquillo MM and Matera
AG: Assignment of a novel bifurcated SET domain gene, SETDB1, to
human chromosome band 1q21 by in situ hybridization and radiation
hybrids. Cytogenet Cell Genet. 84:83–86. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park I, Hwang YJ, Kim T, Viswanath ANI,
Londhe AM, Jung SY, Sim KM, Min SJ, Lee JE, Seong J, et al: In
silico probing and biological evaluation of SETDB1/ESET-targeted
novel compounds that reduce tri-methylated histone H3K9 (H3K9me3)
level. J Comput Aided Mol Des. 31:877–889. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang YK: SETDB1 in early embryos and
embryonic stem cells. Curr Issues Mol Biol. 17:1–10.
2015.PubMed/NCBI
|
|
12
|
Ceol CJ, Houvras Y, Jane-Valbuena J,
Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ,
Ferré F, et al: The histone methyltransferase SETDB1 is recurrently
amplified in melanoma and accelerates its onset. Nature.
471:513–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu PC, Lu JW, Yang JY, Lin IH, Ou DL, Lin
YH, Chou KH, Huang WF, Wang WP, Huang YL, et al: H3K9 histone
methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3
pathway to suppress lung cancer metastasis. Cancer Res.
74:7333–7343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lafuente-Sanchis A, Zúñiga Á, Galbis JM,
Cremades A, Estors M, Martínez-Hernández NJ and Carretero J:
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of
non-small cell lung cancer. Clin Transl Oncol. 18:798–804. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun QY, Ding LW, Xiao JF, Chien W, Lim SL,
Hattori N, Goodglick L, Chia D, Mah V, Alavi M, et al: SETDB1
accelerates tumourigenesis by regulating the WNT signalling
pathway. J Pathol. 235:559–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spyropoulou A, Gargalionis A, Dalagiorgou
G, Adamopoulos C, Papavassiliou KA, Lea RW, Piperi C and
Papavassiliou AG: Role of histone lysine methyltransferases SUV39H1
and SETDB1 in gliomagenesis: Modulation of cell proliferation,
migration, and colony formation. Neuromolecular Med. 16:70–82.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiba T, Saito T, Yuki K, Zen Y, Koide S,
Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, et al:
Histone lysine methyltransferase SUV39H1 is a potent target for
epigenetic therapy of hepatocellular carcinoma. Int J Cancer.
136:289–298. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rivière L, Gérossier L, Hantz O and
Neuveut C: Hepatitis B virus and chromatin remodeling: HBx
counteracts SETDB1/HP1/H3K9me3 transcriptional silencing. Med Sci.
32:455–458. 2016.(In French).
|
|
19
|
Cicchini C, Battistelli C and Tripodi M:
SETDB1 is a new promising target in HCC therapy. Chin Clin Oncol.
5:732016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fei Q, Shang K, Zhang J, Chuai S, Kong D,
Zhou T, Fu S, Liang Y, Li C, Chen Z, et al: Histone
methyltransferase SETDB1 regulates liver cancer cell growth through
methylation of p53. Nat Commun. 6:86512015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Regina C, Compagnone M, Peschiaroli A,
Lena A, Annicchiarico-Petruzzelli M, Piro MC, Melino G and Candi E:
Setdb1, a novel interactor of DeltaNp63, is involved in breast
tumorigenesis. Oncotarget. 7:28836–28848. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Cai K, Wang J, Wang X, Cheng K,
Shi F, Jiang L, Zhang Y and Dou J: MiR-7, inhibited indirectly by
LincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of
breast cancer stem cells by downregulating the STAT3 pathway. Stem
Cells. 32:2858–2868. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lindgren D, Sjödahl G, Lauss M, Staaf J,
Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson
W, et al: Integrated genomic and gene expression profiling
identifies two major genomic circuits in urothelial carcinoma. PloS
One. 7:e388632012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun Y, Wei M, Ren SC, Chen R, Xu WD, Wang
FB, Lu J, Shen J, Yu YW, Hou JG, et al: Histone methyltransferase
SETDB1 is required for prostate cancer cell proliferation,
migration and invasion. Asian J Androl. 16:319–324. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adam L, Vadlamudi RK, McCrea P and Kumar
R: Tiam1 overexpression potentiates heregulin-induced lymphoid
enhancer factor-1/beta -catenin nuclear signaling in breast cancer
cells by modulating the intercellular stability. J Biol Chem.
276:28443–28450. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang J, Ye X, Guan J, Chen B, Li Q, Zheng
X, Liu L, Wang S, Ding Y, Ding Y and Chen L: Tiam1 is associated
with hepatocellular carcinoma metastasis. Int J Cancer. 132:90–100.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ooft M, van Ipenburg J, van Loo R, de Jong
R, Moelans C, Braunius W, de Bree R, van Diest P, Koljenović S,
Baatenburg de Jong R, et al: Molecular profile of nasopharyngeal
carcinoma: Analysing tumour suppressor gene promoter
hypermethylation by multiplex ligation-dependent probe
amplification. J Clin Pathol. 71:351–359. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roy Chattopadhyay N, Das P, Chatterjee K
and Choudhuri T: Higher incidence of nasopharyngeal carcinoma in
some regions in the world confers for interplay between genetic
factors and external stimuli. Drug Discov Ther. 11:170–180. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakanishi Y, Wakisaka N, Kondo S, Endo K,
Sugimoto H, Hatano M, Ueno T, Ishikawa K and Yoshizaki T:
Progression of understanding for the role of Epstein-Barr virus and
management of nasopharyngeal carcinoma. Cancer Metastasis Rev.
36:435–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ooft ML, van Ipenburg JA, Braunius WW,
Zuur CI, Koljenović S and Willems SM: Prognostic role of tumor
infiltrating lymphocytes in EBV positive and EBV negative
nasopharyngeal carcinoma. Oral Oncol. 71:16–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim KY, Le QT, Yom SS, Ng RHW, Chan KCA,
Bratman SV, Welch JJ, Divi RL, Petryshyn RA and Conley BA: Clinical
utility of epstein-barr virus DNA testing in the treatment of
nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys.
98:996–1001. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dai J, Shen W, Wen W, Chang J, Wang T,
Chen H, Jin G, Ma H, Wu C, Li L, et al: Estimation of heritability
for nine common cancers using data from genome-wide association
studies in Chinese population. Int J Cancer. 140:329–336. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He R, Hu Z, Wang Q, Luo W, Li J, Duan L,
Zhu YS and Luo DX: The role of long non-coding RNAs in
nasopharyngeal carcinoma: As systemic review. Oncotarget.
8:16075–16083. 2017.PubMed/NCBI
|
|
34
|
Fountzilas G, Psyrri A, Giannoulatou E,
Tikas I, Manousou K, Rontogianni D, Ciuleanu E, Ciuleanu T, Resiga
L, Zaramboukas T, et al: Prevalent somatic BRCA1 mutations shape
clinically relevant genomic patterns of nasopharyngeal carcinoma in
Southeast Europe. Int J Cancer. 142:66–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Liu W, Zhao Z, Zhang Y, Xiao H and
Luo B: Filaggrin gene polymorphism associated with Epstein-Barr
virus-associated tumors in China. Virus Genes. 53:532–537. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhen Y, Fang W, Zhao M, Luo R, Liu Y, Fu
Q, Chen Y, Cheng C, Zhang Y and Liu Z:
miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4
suppresses cell growth, metastasis, and sensitizes nasopharyngeal
carcinoma to cisplatin. Oncogene. 36:275–285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao H, Yu Z, Bi D, Jiang L, Cui Y, Sun J
and Ma R: Akt/PKB interacts with the histone H3 methyltransferase
SETDB1 and coordinates to silence gene expression. Mol Cell
Biochem. 305:35–44. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schultz DC, Ayyanathan K, Negorev D, Maul
GG and Rauscher FJ III: SETDB1: A novel KAP-1-associated histone
H3, lysine 9-specific methyltransferase that contributes to
HP1-mediated silencing of euchromatic genes by KRAB zinc-finger
proteins. Genes Dev. 16:919–932. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Karanth AV, Maniswami RR, Prashanth S,
Govindaraj H, Padmavathy R, Jegatheesan SK, Mullangi R and
Rajagopal S: Emerging role of SETDB1 as a therapeutic target.
Expert Opin Ther Targets. 21:319–331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ho YJ, Lin YM, Huang YC, Chang J, Yeh KT,
Lin LI, Gong Z, Tzeng TY and Lu JW: Significance of histone
methyltransferase SETDB1 expression in colon adenocarcinoma. APMIS.
125:985–995. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Na HH, Noh HJ, Cheong HM, Kang Y and Kim
KC: SETDB1 mediated FosB expression increases the cell
proliferation rate during anticancer drug therapy. BMB Rep.
49:238–243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Olcina MM, Leszczynska KB, Senra JM, Isa
NF, Harada H and Hammond EM: H3K9me3 facilitates hypoxia-induced
p53-dependent apoptosis through repression of APAK. Oncogene.
35:793–799. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wong CM, Wei L, Law CT, Ho DW, Tsang FH,
Au SL, Sze KM, Lee JM, Wong CC and Ng IO: Up-regulation of histone
methyltransferase SETDB1 by multiple mechanisms in hepatocellular
carcinoma promotes cancer metastasis. Hepatology. 63:474–487. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rivière L, Gerossier L, Ducroux A, Dion S,
Deng Q, Michel ML, Buendia MA, Hantz O and Neuveut C: HBx relieves
chromatin-mediated transcriptional repression of hepatitis B viral
cccDNA involving SETDB1 histone methyltransferase. J Hepatol.
63:1093–1102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thompson PJ, Dulberg V, Moon KM, Foster
LJ, Chen C, Karimi MM and Lorincz MC: Correction: hnRNP K
coordinates transcriptional silencing by SETDB1 in embryonic stem
cells. PLoS Genet. 12:e10063902016. View Article : Google Scholar : PubMed/NCBI
|
